A detailed history of Israel Englander (Millennium Management LLC) transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 175,705 shares of RCUS stock, worth $2.76 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
175,705
Previous 50,000 251.41%
Holding current value
$2.76 Million
Previous $944,000 183.37%
% of portfolio
0.0%
Previous 0.0%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$14.59 - $18.48 $2.56 Million - $3.25 Million
175,705 New
175,705 $2.68 Million
Q4 2023

Feb 14, 2024

SELL
$13.43 - $19.63 $321,661 - $470,158
-23,951 Reduced 43.28%
31,394 $599,000
Q2 2023

Aug 14, 2023

BUY
$16.97 - $22.03 $939,204 - $1.22 Million
55,345 New
55,345 $1.12 Million
Q4 2022

Feb 14, 2023

BUY
$19.7 - $35.71 $2.6 Million - $4.72 Million
132,066 Added 1051.4%
144,627 $2.99 Million
Q3 2022

Nov 14, 2022

SELL
$23.23 - $30.07 $2.58 Million - $3.34 Million
-111,199 Reduced 89.85%
12,561 $329,000
Q2 2022

Aug 15, 2022

BUY
$17.23 - $37.73 $1.69 Million - $3.71 Million
98,303 Added 386.15%
123,760 $3.14 Million
Q1 2022

May 16, 2022

SELL
$28.92 - $41.83 $1.4 Million - $2.03 Million
-48,438 Reduced 65.55%
25,457 $803,000
Q4 2021

Feb 14, 2022

BUY
$31.38 - $48.47 $1.95 Million - $3.01 Million
62,151 Added 529.21%
73,895 $2.99 Million
Q3 2021

Nov 15, 2021

SELL
$26.93 - $37.68 $4.34 Million - $6.07 Million
-160,988 Reduced 93.2%
11,744 $410,000
Q2 2021

Aug 16, 2021

BUY
$22.75 - $35.77 $3.3 Million - $5.19 Million
144,969 Added 522.17%
172,732 $4.74 Million
Q1 2021

May 17, 2021

BUY
$26.16 - $41.39 $284,908 - $450,778
10,891 Added 64.55%
27,763 $780,000
Q4 2020

Feb 16, 2021

SELL
$17.0 - $32.36 $4.86 Million - $9.26 Million
-286,157 Reduced 94.43%
16,872 $438,000
Q3 2020

Nov 16, 2020

SELL
$17.14 - $25.47 $2.85 Million - $4.24 Million
-166,378 Reduced 35.44%
303,029 $5.19 Million
Q2 2020

Aug 14, 2020

BUY
$13.97 - $36.56 $219,594 - $574,686
15,719 Added 3.46%
469,407 $11.6 Million
Q1 2020

May 14, 2020

BUY
$8.78 - $19.28 $2.66 Million - $5.84 Million
302,739 Added 200.56%
453,688 $6.3 Million
Q4 2019

Feb 14, 2020

SELL
$7.33 - $10.79 $275,241 - $405,164
-37,550 Reduced 19.92%
150,949 $1.53 Million
Q3 2019

Nov 14, 2019

BUY
$6.44 - $10.18 $713,313 - $1.13 Million
110,763 Added 142.49%
188,499 $1.72 Million
Q2 2019

Aug 15, 2019

SELL
$7.29 - $13.38 $738,440 - $1.36 Million
-101,295 Reduced 56.58%
77,736 $618,000
Q2 2019

Aug 14, 2019

BUY
$7.29 - $13.38 $1.31 Million - $2.4 Million
179,031 New
179,031 $15.7 Million
Q4 2018

Feb 14, 2019

SELL
$9.74 - $14.5 $1.37 Million - $2.05 Million
-141,077 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$10.88 - $14.95 $1.24 Million - $1.7 Million
113,654 Added 414.45%
141,077 $1.97 Million
Q2 2018

Aug 14, 2018

SELL
$12.24 - $17.05 $2.19 Million - $3.04 Million
-178,518 Reduced 86.68%
27,423 $336,000
Q1 2018

May 15, 2018

BUY
$15.44 - $17.71 $3.18 Million - $3.65 Million
205,941 New
205,941 $3.18 Million

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.14B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.